Brief: Vertex Pharmaceuticals Inc - FDA Expands Indication For Trikafta In Cf Patients Ages 2 And Older
01/04/2026 13:35
Vertex Pharmaceuticals Inc VRTX.O: VERTEX ANNOUNCES US FDA APPROVAL FOR LABEL EXTENSIONS OF ALYFTREK® AND TRIKAFTA®, EXPANDING AVAILABILITY OF THESE MEDICINES TO ~95% OF ALL PEOPLE WITH CF IN THE UNITED STATES VERTEX PHARMACEUTICALS INC - FDA EXPANDS INDICATION FOR TRIKAFTA IN CF PATIENTS AGES 2 AND OLDER Source text: ID:nBw1FdLsya Further company coverage: VRTX.O
Recent news on Vertex Pharmaceuticals
See all newsBrief: Vertex Announces US FDA Acceptance Of Biologics License Application For Accelerated Approval Of Povetacicept In IgA Nephropathy
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings
Vertex Q1 adjusted EPS beats estimates, revenue rises 8%
Vertex tops profit estimates as sales of new cystic fibrosis drug surge
Brief: Vertex Pharmaceuticals Q1 Adjusted EPS USD 4.47 Vs. IBES Estimate USD 4.31